Back to today’s briefing

Story perspectives

New Treatment Shows 60.9% Success for Colorectal Cancer

1/27/2025

50 9

Summary

Story summary

In a groundbreaking Phase III BREAKWATER trial, patients with BRAF V600E-mutant metastatic colorectal cancer experienced a remarkable 60.9% response rate when treated with a powerful combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy. This promising regimen outperformed standard care, paving the way for a potential new first-line treatment that could significantly improve patient outcomes.

1 of 1

Story summary

In a groundbreaking Phase III BREAKWATER trial, patients with BRAF V600E-mutant metastatic colorectal cancer experienced a remarkable 60.9% response rate when treated with a powerful combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy. This promising regimen outperformed standard care, paving the way for a potential new first-line treatment that could significantly improve patient outcomes.